Clinical Trial Detail

NCT ID NCT02719691
Title Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Colorado, Denver

triple-receptor negative breast cancer

Advanced Solid Tumor


Alisertib + Sapanisertib

Age Groups: senior adult

No variant requirements are available.